Cleveland Clinic | Strategic Alliance Partners

April 13, 2017

Shlomo Koyfman, MD, discusses the findings of a recent study of patients with HPV-positive oropharyngeal cancer treated with cisplatin-based chemoradiotherapy or cetuximab-based bioradiotherapy.

April 12, 2017

The presence of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells predicted poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies, according to results recently published in the Journal of Clinical Oncology.

March 23, 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses informing patients of reirradiation as a treatment for head and neck cancer.

March 16, 2017

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) reirradiation for patients with head and neck cancer.

January 20, 2017

Jame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, discusses a head cooling system that can be used to limit hair loss attributed to chemotherapy treatment for patients with breast cancer.

January 19, 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses recent advancements in reirradiation treatment for patients with head and neck cancer.

January 17, 2017

Rahul Tendulkar, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses post-prostatectomy radiation therapy and its impact on reducing prostate cancer mortality.

January 09, 2017

Alberto J. Montero, MD, Department of Hematology and Oncology at Cleveland Clinic, discusses the PERTAIN study in postmenopausal women with hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer. The study looks at the impact of adding pertuzumab (Perjeta) to trastuzumab (Herceptin) in aromatase inhibitor (AI) therapy.

December 15, 2016

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses risk categories that stratified patients in a study evaluating intensity-modulated radiation therapy and stereotactic body radiation therapy to determine outcomes in the reirradiation setting for recurrent head and neck cancer.

November 01, 2016

Samuel Chao, MD, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, discusses spine stereotactic radiosurgery for the treatment of metastases located on the spine.

October 26, 2016

Vamsidhar Velcheti, MD, an assistant professor of Medicine at Cleveland Clinic Lerner School of Medicine, discusses the ALK inhibitor alectinib (Alecensa) and what potential the agent could have in the frontline setting for patients with ALK-positive non–small cell lung cancer (NSCLC). Velcheti shared this insight in an interview during the 2016 OncLive State of the Science Summit on Non–Small Cell Lung Cancer.

October 05, 2016

Kevin Stephans, MD, associate staff, Radiation Oncology at Cleveland Clinic, discusses advancements in the treatment of patients with oligometastatic lung cancer.

September 20, 2016

Despite the fervent advocacy of stereotactic radiosurgery alone, the addition of whole-brain radiation therapy clearly improves local control, decreases distant brain failure, minimizes the need for salvage therapies such as surgery, and, most importantly, decreases neurologic death.

September 08, 2016

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

September 08, 2016

Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.

August 31, 2016

Nathan Pennell, MD, PhD, associate professor of Medicine at Cleveland Clinic, discusses the importance of testing patients with non–small cell lung cancer (NSCLC) to determine if they harbor the EGFR mutation, as well as the agents available to target that genetic abnormality.

April 24, 2016

Although precision oncology has promise, its success hinges on the availability of clinical trials of targeted therapies.

March 09, 2016

Jorge Garcia, MD, discusses CheckMate-025, the challenges with PD-1 as a biomarker, additional potential biomarkers, and why combination immunotherapy in renal cell carcinoma is still a work in progress.

December 26, 2015

One of the central reasons that curing cancer has been so problematic is the dysfunction of TP53, the single most common genetic alteration in cancer.

October 19, 2015

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.